Related Experiment Video
Updated: May 13, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet therapy: present status and future prospects
Justin R Hamilton1, Zane Kaplan, Shaun P Jackson
1Australian Centre for Blood Diseases, Monash University, 6th Level, Burnet Building, AMREP Campus, 89 Commercial Road, Melbourne, Victoria 3004, Australia +61 3 9903 0122 ; +61 3 9903 0228 ; Justin.Hamilton@med.monash.edu.au.
Insights
Platelet accumulation causes arterial thrombosis, leading to heart attacks and strokes. Current antiplatelet therapies aim to improve treatment safety and effectiveness for cardiovascular disease management.
Area of Science:
- Cardiovascular Science
- Hematology
- Pharmacology
Background:
- Platelet accumulation at vascular injury sites drives arterial thrombosis.
- Arterial thrombosis underlies acute coronary syndromes and ischemic stroke, major causes of death.
- Platelets are a primary therapeutic target in cardiovascular disease management.
Purpose of the Study:
- To review the current landscape of antiplatelet therapy.
- To explore future strategies for enhancing antiplatelet agent safety and efficacy.
Main Methods:
- Literature review and perspective synthesis.
- Analysis of current antiplatelet drug classes.
- Discussion of emerging therapeutic approaches.
Main Results:
- Antiplatelet therapy is crucial but faces challenges in balancing efficacy and bleeding risk.
- Existing agents target various platelet activation pathways.
- Novel strategies are being developed to optimize therapeutic outcomes.
Conclusions:
- Antiplatelet therapy remains a cornerstone in managing thrombotic cardiovascular diseases.
- Future directions focus on personalized medicine and improved safety profiles.
- Optimizing antiplatelet strategies is essential for reducing morbidity and mortality.
Abstract:
The excessive accumulation of platelets at sites of vascular injury is a key event in the development of arterial thrombosis, the principal pathogenic mechanism underlying the acute coronary syndromes and ischaemic stroke. In combination, these disorders are the leading causes of morbidity and mortality in the industrialised world and, as a consequence, the platelet is a major therapeutic target in the management of cardiovascular disease. This perspective focuses on the present state of antiplatelet therapy and potential future strategies to improve the safety and efficacy of antiplatelet agents.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins

